OncoMatch/Clinical Trials/NCT07079228

A Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic Cancer

Is NCT07079228 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments for pancreatic cancer.

Phase 3RecruitingQilu Pharmaceutical Co., Ltd.NCT07079228Data as of May 2026

Treatment: QLS31905 · Nab-paclitaxel. · Gemcitabine · Nab-paclitaxel. · Gemcitabine — The goal of this study is to evaluate the efficacy of QLS31905 in combination with chemotherapy (nab-paclitaxel plus gemcitabine \[AG\]) versus placebo in combination with chemotherapy (AG) in the treatment of CLDN18.2-positive advanced pancreatic cancer in adult participants.

Check if I qualify

Extracted eligibility criteria

Cancer type

Pancreatic Cancer

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Lab requirements

Kidney function

adequate renal function

Liver function

adequate liver function

Cardiac function

adequate cardiac function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify